Design, synthesis, and biological evaluation of imidazolidinone derivatives as potent PPARα/δ agonists for the treatment of cholestatic liver diseases.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zhuoxin,Fu

第一单位： Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.

作者： Zhuoxin,Fu ^[1] ; Xin,Liu ^[1] ; Wenhui,Yu ^[1] ; Yufan,Kuang ^[1] ; Fengqin,Wang ^[1] ; Zhiqiang,Qian ^[1] ; Qinglong,Xu ^[2] ; Liang,Dai ^[3] ; Zhiqi,Feng ^[4]

作者单位： Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. ^[1] Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: qlxu@cpu.edu.cn. ^[2] Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: dailiang@cpu.edu.cn. ^[3] Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: fzq@cpu.edu.cn. ^[4]

关键词 Cholestatic liver disease Imidazolidinone Nuclear receptor PPARs